JAK2 and non-small cell lung carcinoma: proved that silibinin inhibits NSCLC cell PD-L1 expression by suppressing PI3K/AKT molecular phosphorylation, and silibinin also influences PD-L1 expression through JAK2/STAT5 signaling (176).